Olmetec Plus Dosage/Direction for Use

Adults: Olmetec Plus is administered once daily, with or without food, in patients whose blood pressure is not adequately controlled by olmesartan medoxomil or hydrochlorothiazide alone. When clinically appropriate, direct change from monotherapy to the fixed combination may be considered. Dose titration of the individual components is recommended: Olmetec Plus 20/12.5-mg tab may be administered in patients whose blood pressure is not adequately controlled with hydrochlorothiazide 12.5 or 25 mg monotherapy, or Olmetec 20 mg alone. If additional blood pressure lowering is required the dose of each monocomponent may be titrated to the strength of Olmetec Plus 40/12.5-mg tab and subsequently, if required to 40/25-mg tab.
Olmetec Plus 40/12.5 mg and 40/25mg may be administered in patients whose blood pressure is not adequately controlled by Olmetec 40 mg alone, hydrochlorothiazide alone, or Olmetec Plus 20/12.5 mg.
Renal Impairment: In patients with mild to moderate renal impairment [creatinine clearance (CrCl) of 30-60 mL/min] the dosage of olmesartan medoxomil should not exceed 20 mg daily (ie, Olmetec Plus 20/12.5 mg), owing to limited experience of higher dosages of Olmetec in this patient group (see Pharmacokinetics under Actions). When Olmetec Plus is used in such patients, periodic monitoring of renal function is advised (see Precautions).
Hepatic Impairment: The use of Olmetec Plus in patients with hepatic impairment is not recommended since there is currently limited experience of olmesartan medoxomil in this patient group (see Pharmacokinetics under Actions and Precautions).
Children and Adolescents: The safety and efficacy of Olmetec plus have not been established in children and adolescents up to 18 years.
Elderly: No initial dosage adjustments is recommended for elderly patients (see Pharmacokinetics under Actions).
Administration: Taken once daily, with or without food.